{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:14:48Z","timestamp":1776773688124,"version":"3.51.2"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1097\/dad.0000000000000274","type":"journal-article","created":{"date-parts":[[2015,2,12]],"date-time":"2015-02-12T11:22:40Z","timestamp":1423740160000},"page":"e57-e60","source":"Crossref","is-referenced-by-count":4,"title":["Targeting the Adnexal Epithelium"],"prefix":"10.1097","volume":"37","author":[{"given":"JiaDe","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sitara","family":"Ravikumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A.","family":"Plaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James L.","family":"Troy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan M.","family":"Schieke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-18-20210202","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":". Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"R2-18-20210202","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":". Mutations of the BRAF gene in human cancer.","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R3-18-20210202","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":". Inhibition of mutated, activated BRAF in metastatic melanoma.","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"R4-18-20210202","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2012.06.045","article-title":". Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.","volume":"67","author":"Boyd","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R5-18-20210202","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":". RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"R6-18-20210202","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdt015","article-title":". Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.","volume":"24","author":"Boussemart","year":"2013","journal-title":"Ann Oncol"},{"key":"R7-18-20210202","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/exd.12249","article-title":". No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.","volume":"22","author":"Ganzenmueller","year":"2013","journal-title":"Exp Dermatol"},{"key":"R8-18-20210202","first-page":"521","article-title":". Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.","volume":"164","author":"Siegel","year":"2011","journal-title":"Br J Dermatol"},{"key":"R9-18-20210202","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2133.2011.10744.x","article-title":". Dermatological phenotype in costello syndrome: consequences of ras dysregulation in development.","volume":"166","author":"Siegel","year":"2012","journal-title":"Br J Dermatol"},{"key":"R10-18-20210202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":". Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"R11-18-20210202","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/j.jaad.2012.02.038","article-title":". Eccrine squamous syringometaplasia associated with vemurafenib therapy.","volume":"67","author":"Story","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"R12-18-20210202","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/cup.12317","article-title":". The changes in the expression levels of follicular markers in keratoacanthoma depend on the stage: keratoacanthoma is a follicular neoplasm exhibiting infundibularisthmic differentiation without expression of CK15.","volume":"41","author":"Misago","year":"2014","journal-title":"J Cutan Pathol"},{"key":"R13-18-20210202","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/cup.12350","article-title":". The histopathologic changes in keratoacanthoma depend on its stage.","volume":"41","author":"Misago","year":"2014","journal-title":"J Cutan Pathol"},{"key":"R14-18-20210202","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1111\/bjd.12519","article-title":". Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.","volume":"169","author":"Anforth","year":"2013","journal-title":"Br J Dermatol"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000000274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:45Z","timestamp":1620950445000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201505000-00018"}},"subtitle":["An Unusual Case of Syringometaplasia in a Patient on Vemurafenib"],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000274","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]}}}